Ann Surg Oncol

1. ZAGER JS, John J
   Response to Letter to the Editor Regarding: An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
   Ann Surg Oncol. 2025 Aug 21. doi: 10.1245/s10434-025-18092.
   

   >> Share

   
   
2. TAYLOR CD, Niba VS, Baskin AS, Mott NM, et al
   Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.
   Ann Surg Oncol. 2025 Aug 16. doi: 10.1245/s10434-025-18063.
   

   >> Share

   
   

   
   BMC Ophthalmol

3. ROS-SANCHEZ E, Oliver-Gutierrez D, Buck P, Goncharova-Simon T, et al
   Multimodal imaging of tumour-related lipid exudation and exudative retinal detachment following brachytherapy in choroidal melanoma.
   BMC Ophthalmol. 2025;25:467.
   

   >> Share

   
   
4. KROHN J, Vinnem LIH, Jansson RW, Straume O, et al
   Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review.
   BMC Ophthalmol. 2025;25:464.
   

   >> Share

   
   

   
   Br J Dermatol

5. ZHANG WW, Ke LF, Chen Y, Wu CY, et al
   Methylation-Based Test for Diagnosis of Benign and Malignant Melanocytoma.
   Br J Dermatol. 2025 May 2:ljaf169. doi: 10.1093.
   

   >> Share

   
   

   
   Cancer Res

6. FLEM-KARLSEN K, Talty R, McGeary MK, Park K, et al
   Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma that Drives Antitumor Immunity.
   Cancer Res. 2025 Aug 19. doi: 10.1158/0008-5472.CAN-24-1952.
   

   >> Share

   
   
7. SHAN JL, Zhang KM, Zhong WQ, Yang XY, et al
   Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors.
   Cancer Res. 2025;85:3015-3031.
   

   >> Share

   
   

   
   Clin Cancer Res

8. NOH KW, Tolkach Y, Helbig D, Mitchell Barroso V, et al
   Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanoma.
   Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0889.
   

   >> Share

   
   
9. FA'AK F, Coudray N, Jour G, Ibrahim M, et al
   Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
   Clin Cancer Res. 2025;31:3526-3536.
   

   >> Share

   
   

   
   J Am Acad Dermatol

10. SHELTON E, Kaur S, Figueroa Baiges A, Patel J, et al
    Assessing the Protective Role of Sirolimus Against Non-Melanoma Skin Cancer: A Case Series.
    J Am Acad Dermatol. 2025 Aug 15:S0190-9622(25)02600.
    

    >> Share

    
    

    
    J Invest Dermatol

11. CHAN AA, Noguti J, Ramirez NM, Navarrete M, et al
    Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence.
    J Invest Dermatol. 2025 Aug 18:S0022-202X(25)02342.
    

    >> Share

    
    

    
    JAMA

12. JOSHI UM, Kashani-Sabet M, Kirkwood JM
    Cutaneous Melanoma: A Review.
    JAMA. 2025 Aug 25. doi: 10.1001/jama.2025.13074.
    

    >> Share

    
    

    
    Nat Med

13. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
    Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
    Nat Med. 2025 Aug 14. doi: 10.1038/s41591-025-03875.
    

    >> Share

    
    
14. YAN S, Yu Z, Primiero C, Vico-Alonso C, et al
    A multimodal vision foundation model for clinical dermatology.
    Nat Med. 2025;31:2691-2702.
    

    >> Share

    
    

    
    PLoS One

15. KOSHAREK AT, Zuleger CL, Glass WS, Eickhoff J, et al
    In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma.
    PLoS One. 2025;20:e0330200.
    

    >> Share

    
    
16. TOLD R, Reumueller A, Kreminger J, Sacu S, et al
    Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.
    PLoS One. 2025;20:e0328360.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share